Literature DB >> 9261310

Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative.

D Husain1, J W Miller, A G Kenney, N Michaud, T J Flotte, E S Gragoudas.   

Abstract

PURPOSE: To study the efficacy of liposomal benzoporphyrin derivative (BPD) (Verteportin) for the angiographic visualization and photodynamic therapy (PDT) of experimental iris neovascularization.
METHODS: Experimental iris neovascularization was induced in eight cynomolgus monkey eyes by occluding all the branch retinal veins with a dye-yellow (577-nm) laser. Iris angiography was done with sodium fluorescein, indocyanine green (ICG), and liposomal BPD to compare the visualization of normal and neovascular vessels by these three dyes. PDT was performed using an intravenous infusion of liposomal BPD (0.375-0.75 mg/kg), followed by irradiation with 689-nm light from a diode laser/slit-lamp delivery system using 600 mW/cm2 irradiance and 150 J/cm2 fluence. The effect of treatment was followed by iris photography and angiography, and the findings were confirmed by histopathology using light and electron microscopy.
RESULTS: Iris fluorescein angiography (FA) showed superficial tortuous and leaky new vessels. Liposomal BPD and ICG angiography of the same eye demonstrated deeper dilated and tortuous iris vessels, with minimal dye leakage. PDT of the iris with irradiation, performed within 20 minutes of the start of dye infusion (0.75 mg/kg), resulted in angiographic and histologic occlusion of iris vessels examined at 24 hours. Three to nine days after PDT, histopathologic examination showed regression of the iris neovascular membrane, with some open vessels.
CONCLUSIONS: Liposomal BPD and ICG provided angiographic visualization of deeper normal and neovascular iris vessels. PDT using liposomal BPD leads to effective early closure to experimental iris neovascularization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261310     DOI: 10.1016/s0161-6420(97)30151-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Auto-cortex of crystalline lens-induced iris neovascularization.

Authors:  Lin Liu; Yong-Ping Li; Bo Zhang; Wen-Xin Zhang
Journal:  Int J Ophthalmol       Date:  2012-02-18       Impact factor: 1.779

Review 2.  Photodynamic therapy: a review.

Authors:  J S McCaughan
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

3.  An Experimental Animal Model of Photodynamic Optic Nerve Head Injury (PONHI).

Authors:  Dimosthenis Mantopoulos; Peggy Bouzika; Athanassios Tsakris; Basil S Pawlyk; Michael A Sandberg; Joan W Miller; Joseph F Rizzo Iii; Demetrios G Vavvas; Dean M Cestari
Journal:  Curr Eye Res       Date:  2016-05-09       Impact factor: 2.424

Review 4.  Age-related macular degeneration: epidemiology and optimal treatment.

Authors:  Morten la Cour; Jens Folke Kiilgaard; Mogens Holst Nissen
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008

6.  The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.

Authors:  Lan-Hsin Chuang; Yih-Shiou Hwang; Nan-Kai Wang; Yen-Po Chen; Laura Liu; Ling Yeung; Kuan-Jen Chen; Tun-Lu Chen; Wei-Chi Wu; Chi-Chun Lai
Journal:  J Ocul Pharmacol Ther       Date:  2014-06-20       Impact factor: 2.671

7.  Photodynamic therapy for recurrent hyphema after proton beam radiotherapy of iris melanoma.

Authors:  Nikolaos Trichopoulos; Bertil Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-12       Impact factor: 3.117

8.  Verteporfin-induced formation of protein cross-linked oligomers and high molecular weight complexes is mediated by light and leads to cell toxicity.

Authors:  Eleni K Konstantinou; Shoji Notomi; Cassandra Kosmidou; Katarzyna Brodowska; Ahmad Al-Moujahed; Fotini Nicolaou; Pavlina Tsoka; Evangelos Gragoudas; Joan W Miller; Lucy H Young; Demetrios G Vavvas
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.